Quick Answer
Compounded tirzepatide costs $299 to $549 per month in 2026 through US-licensed telehealth providers, depending on the provider, the dose, and the commitment tier.
Brand-name tirzepatide by comparison costs much more without insurance:
Compounded preparations are not FDA-approved as final products. The active pharmaceutical ingredient is FDA-registered. The price difference reflects production cost, not lower quality at accredited pharmacies.
2026 Compounded Tirzepatide Pricing (Real Numbers)
Pricing verified June 2026 against each provider's published pricing page. Re-verify quarterly; telehealth pricing changes often. All prices reflect cash pricing without insurance, in USD.
| Provider | Plan | First month | Ongoing | All-inclusive? |
|---|---|---|---|---|
| Majesta Health | Performance (tirzepatide injection) | $329 | $399/month | Yes (physician, medication, shipping, messaging, Month 6 included) |
| Hims & Hers | Compounded tirzepatide injection | $299 (with longer prepay) | $299 to $549/month | Tiered by commitment |
| Ro (Roman) | Compounded tirzepatide injection | $299 (longest commitment) | $299 to $499/month | Tiered by commitment |
| Henry Meds | Compounded tirzepatide | $369 to $499/month | Same | Multiple commitment tiers |
| Mochi Health | Compounded tirzepatide + coaching | $79 membership + medication | Varies by dose | Membership plus medication structure |
For a broader walkthrough of buying compounded tirzepatide online, see our compounded tirzepatide online in 2026 guide.
Brand-Name Comparison
For context, here is what brand-name tirzepatide costs in 2026 without insurance:
| Brand | Manufacturer | Cash price per month | Indication |
|---|---|---|---|
| Zepbound (pens) | Eli Lilly | ~$1,086 | FDA-approved for chronic weight management and (since 2024) moderate-to-severe obstructive sleep apnea in adults with obesity |
| Zepbound (vials, LillyDirect self-pay) | Eli Lilly | ~$349 to $499 | Same indication; lower-cost self-pay vials sold direct |
| Mounjaro | Eli Lilly | ~$968 to $1,150 | FDA-approved for type 2 diabetes; often prescribed off-label for weight management |
Eli Lilly's LillyDirect self-pay vials brought brand-name tirzepatide pricing down meaningfully for cash-paying patients. At the lower vial doses, LillyDirect can be competitive with compounded pricing. At higher maintenance doses, the brand vial price rises and the gap widens again.
With commercial insurance coverage, copays for brand-name tirzepatide can be as low as $25 to $100 per month when approved, which often requires prior authorization with documented BMI and comorbidity criteria.
With no insurance coverage, compounded tirzepatide through legitimate US-licensed telehealth is consistently one of the most affordable real paths, alongside LillyDirect vials at lower doses.
For a side-by-side on the medication itself, see our compounded tirzepatide vs Zepbound 2026 comparison.
What the Price Should Include
The headline price is only meaningful if you know what is bundled. A $199 plan that bills consultation, shipping, and refills separately can easily cost more than a $329 plan with everything included.
A legitimate $299 to $549 monthly compounded tirzepatide plan in 2026 should include:
What should NOT be hidden in the fine print:
Why Compounded Is Cheaper
Compounded tirzepatide is not a different molecule. It uses the same FDA-registered active pharmaceutical ingredient as the brand. Three things explain the lower price:
1. No trial recovery cost. The brand price helps recover the cost of the SURMOUNT and SURPASS clinical programs and the FDA approval pathway. Compounded preparations do not carry that. 2. Smaller-batch production. State-licensed 503A and 503B pharmacies compound in smaller batches rather than running global industrial manufacturing lines. 3. No mass marketing premium. A large share of brand cost is sales and advertising. Compounded pricing does not include that.
The trade-off is real and worth stating plainly: compounded preparations are not FDA-approved as final products. The active ingredient is FDA-registered, and accredited pharmacies batch-test every preparation, but the specific compounded formulation has not been reviewed by the FDA the way the brand product has.
Insurance and HSA / FSA Reality (2026)
Commercial insurance almost never covers compounded tirzepatide. Coverage for brand-name (Zepbound or Mounjaro) is variable. Most weight-management-indication coverage requires prior authorization with documented BMI plus comorbidity criteria. Coverage for Mounjaro for diabetes is generally broader than coverage for weight management.
Medicare does not cover GLP-1 and GIP medications for weight loss as of 2026. Medicare Part D covers Mounjaro for the diabetes indication.
Medicaid varies by state. Many state programs cover these medications for diabetes only.
HSA and FSA cards typically reimburse prescription compounded tirzepatide when accompanied by valid documentation. Save your prescription confirmation and pharmacy receipts.
Dose and Price: How Titration Works
Tirzepatide is not a fixed dose. It steps up over time:
At a fair provider, the monthly price stays the same across this titration range. You should not pay more simply because your dose increased on schedule. If a provider's price climbs every time your dose goes up, that is a dose-escalation upcharge, and it can quietly turn a $299 headline into a much higher real cost at maintenance.
The Majesta Performance plan holds one price across the titration phase, so the number you see in month one is the number you plan around.
Hidden Fees to Watch For
The published headline is not the real cost if any of these are billed on the side:
The honest way to compare two providers is to add up the total first-month cost including any one-time fees, then the total ongoing monthly cost with no commitment. Compare those two numbers, not the marketing headline.
How Majesta Performance Prices It
The Majesta Health Performance plan is compounded tirzepatide injection at a flat, all-in price:
Here is the all-in six-month math, which is the comparison that matters for cash-paying patients:
| Plan | Month 1 | Months 2-5 | Month 6 | Total six-month | Average / month |
|---|---|---|---|---|---|
| Majesta Performance (tirzepatide) | $329 | $399 × 4 = $1,596 | $0 (included) | $1,925 | $321 |
| Other compounded providers (mid-tier $449/mo, no Month 6) | $449 | $449 × 4 = $1,796 | $449 | $2,694 | $449 |
| Zepbound pens without insurance | $1,086 | $1,086 × 4 = $4,344 | $1,086 | $6,516 | $1,086 |
The Month 6 medication included benefit applies after five consecutive paid monthly cycles.
Why Pricing Should Not Be the Only Factor
Three factors matter as much as price when evaluating any compounded tirzepatide source:
1. Is the prescribing physician real and US-licensed? Cheap sources often skip this. Skipping medical screening is the actual safety risk. 2. Is the dispensing pharmacy accredited? A 503A or 503B pharmacy with NABP accreditation and LegitScript certification, that batch-tests every preparation for potency and sterility, operates at a much higher safety standard than an unaccredited one. 3. Is ongoing physician access included? Side effects and dose adjustments happen for almost every patient in the first 2 to 3 months. Without a physician you can message, you handle them alone.
In the SURMOUNT-1 trial, published results reported meaningful average weight reduction over 72 weeks at the studied doses (published trial data). That is brand-product trial data, and individual results may vary. No legitimate provider, including Majesta, can promise a specific outcome for you.
The Bottom Line
In 2026, compounded tirzepatide costs $299 to $549 per month through US-licensed telehealth providers. Brand-name pens run roughly 2 to 3 times higher without insurance, while LillyDirect self-pay vials sit closer to compounded pricing at lower doses. With insurance coverage, brand-name copays can compete on math, but coverage for weight management is patchy and often denied without prior authorization.
Compounded preparations are not FDA-approved as final products; the active pharmaceutical ingredient is FDA-registered.
The number that matters is not the headline. It is the all-in monthly cost at a provider with a real US-licensed physician, an accredited compounding pharmacy, one price across your titration range, and ongoing physician access included.
If you want a physician-reviewed recommendation specific to your situation, start your 2-minute medical assessment at /quiz. A US-licensed physician will review your information, screen for contraindications, and confirm the right plan for you.
Related guides
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider. Compounded medications are not FDA-approved as final products. Prices reflect typical 2026 US retail and are subject to change. Individual results may vary.
Frequently Asked Questions
How much does compounded tirzepatide cost per month in 2026?
Through US-licensed telehealth providers, compounded tirzepatide costs $299 to $549 per month in 2026, depending on the provider, the dose, and the commitment tier. Brand-name Mounjaro by comparison is around $968 to $1,150 per month at cash retail, and brand-name Zepbound pens run about $1,086 per month. Eli Lilly's LillyDirect self-pay vials of Zepbound are priced around $349 to $499 per month depending on dose. Compounded preparations are not FDA-approved as final products.
Why is compounded tirzepatide cheaper than Mounjaro or Zepbound?
Brand-name tirzepatide (Mounjaro at around $968 to $1,150 per month, Zepbound pens at about $1,086 per month) carries the cost of the original Phase 3 trials (the SURMOUNT and SURPASS programs), FDA approval, large-scale manufacturing, and marketing. Compounded tirzepatide uses the same FDA-registered active pharmaceutical ingredient prepared in smaller batches at state-licensed 503A or 503B compounding pharmacies. The pricing reflects production cost without the brand premium. The trade-off is that the compounded preparation itself is not FDA-approved as a final product.
Does compounded tirzepatide cost more as the dose goes up?
At a legitimate provider, no. Tirzepatide titrates from a low starting dose (commonly 2.5 mg per week) up through a maintenance range over several months. A fair plan charges the same monthly price across the titration range. If a provider charges more each time your dose increases, that is a dose-escalation upcharge to watch for. The Majesta Performance plan holds one price across the titration phase.
Does insurance cover compounded tirzepatide?
Compounded tirzepatide is almost never covered by commercial insurance, Medicare, or Medicaid. The trade-off is significantly lower cash pricing compared to brand-name. HSA and FSA cards are typically accepted by US-licensed telehealth providers with a valid prescription. If insurance covers brand-name Zepbound at a low copay (under $200 per month), brand-name can win on math. Without that coverage, compounded is the most affordable real option.
Can I use my HSA or FSA card for compounded tirzepatide?
In most cases, yes. HSA and FSA cards typically reimburse prescription compounded tirzepatide when accompanied by valid documentation. Save your prescription confirmation and pharmacy receipts in case your plan administrator asks for them. Most US-licensed telehealth providers accept HSA and FSA cards at checkout the same way they accept a regular debit or credit card.
What hidden fees should I watch for when comparing compounded tirzepatide prices?
Watch for separate consultation fees, shipping fees, refill fees, lab work fees, multi-month prepay requirements to access the published cheapest tier, plan cancellation penalties, paid coaching tiers bundled with the medication, and undisclosed dose-escalation upcharges. The fair way to compare providers is to compute the total first-month cost including any one-time fees, and the total ongoing monthly cost with no commitment.
All Majesta Health medical content is clinically reviewed before publication by US-licensed physicians affiliated with our clinical infrastructure partner, MD Integrations (MDI). Reviewers hold active state medical licenses, are board-certified in primary care or obesity medicine, and specialize in GLP-1 receptor agonist therapy for chronic weight management. MDI is LegitScript certified and SOC 2 Type II accredited.
- US-licensed physicians affiliated with our clinical partner MD Integrations (LegitScript certified, HIPAA, SOC 2 Type II, ISO certified)
- Board-certified in primary care and obesity medicine
- Active state medical licensure required for every prescribing clinician
- Active DEA registration where applicable (note: GLP-1 medications are not controlled substances)
- Telehealth practice across all 50 US states and DC through the MD Integrations Medical Services Organization
- Dispensing pharmacy partner: Belmar Pharma Solutions (LegitScript certified, NABP accredited, 503A and 503B compounding)